top of page
Latest News
Type 2 (T2)-targeted biologics have utility in the management of T2-low asthma, but more effective therapies are needed: Implications of EMBER study
The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα) was associated
7 hours ago3 min read
A recent study shows a surprising improvement in respiratory outcomes when patients with asthma receive weight loss drugs.
Singapore, [10 April 2025] – A large real world evidence study conducted by leading respiratory experts found patients with asthma who...
Apr 82 min read
bottom of page